This week’s edition of the Weekender is a testament to the amazing innovation taking place within the Garden State with many exciting announcements from emerging companies, such as BioNJ Members ContraVir Pharmaceuticals, SCYNEXIS, Cyclacel Pharmaceuticals, Caladrius Biosciences, PTC Therapeutics, PDS Biotechnology, Soligenix, Advaxis, ProStrakan, Immunomedics and more. From new drug approvals to reaching important milestones within the clinical trials process, the New Jersey life sciences ecosystem continues to create hope for Patients.
BioNJ Board Advisor and Former Chairman Dr. Sol J. Barer — one of the founders of Celgene (and one of our faves!) — continues to play an active role in the industry having just been named Special Advisor to the Chairman of Immunomedics, Dr. David M. Goldenberg. (Read more in the “People in the News” section below.)
A special call out to precious 7-year old Patient Advocate “Magic” Max Schill who continues to move the Hill and who spent last week there advocating for the Senate’s version of the 21st Century Cures Act, Innovations for Healthier Americans Act, that could help him and millions of others with rare diseases. The 21st Century Cures Act already passed the House of Representatives. Max visited nearly all of the 100 Senate offices across two days, leaving his artwork at each one. Click here to watch “Magic” Max on CBS News.
Visit www.BioNJ.org to learn about the many upcoming events being hosted by BioNJ, including our HR Conference on May 12 and BioNJ’s Sixth Annual International BioPartnering Conference on May 26.
Click here to read this week’s Weekender.